The FDA has approved the first ever disease modifying treatment in Alzheimer’s disease. Our research team was one of the leading enrollers in the world for this study. We cannot thank the patients enough for their contributions and commitment to the Biogen studies for aducanumab.
Without their willingness to join these clinical trials, we would not have access to the first ever drug aimed at slowing progression of symptoms of the disease.
Congratulations to Biogen and all the scientists around the world who worked tirelessly for years on these clinical trials. We look forward to making this available to our patients.